Sitemap - 2021 - PsyMed Ventures Newsletter
MAPS PBC, rethinking the pharma business model and MDMA-assisted therapy
The new frontiers of DMT therapies
Scaling psilocybin therapy: Compass Pathways' Lars Wilde
Ready for some psychedelic science?
Analyzing the atai Life Sciences IPO
A 30 year journey towards ibogaine approval: Deborah Mash, CEO of DemeRx
👋Clubhouse: Understanding Psychedelic Medicine Startups
TOMORROW 👋Clubhouse: What’s new with Ketamine Psychotherapy
Founder of The Trip Report, Zach Haigney: Clinical trials, media, reciprocity, open science
Wednesday: 👋Clubhouse on Natural vs. Synthetic Psychedelic Medicine
How To (Legally) Make Psychedelic Medicine: CEO of Psygen, Danny Motyka
Tomorrow: 👋Clubhouse with Rick Doblin & Rachel Yehuda on MDMA-Assisted Therapy